Mylan Says King Pharma Deal Unlikely
561858
-- Mylan Laboratories  Inc.MYL.N on Wednesday said it is unlikely to complete its  $3.37 billion acquisition of King Pharmaceuticals Inc.KG.N at  the current price because of King's need to restate earnings.
38488
Generic drug maker Mylan Laboratories Inc. reaffirmed on Wednesday its planned $3.37 billion purchase of King Pharmaceuticals Inc.
741365
PITTSBURGH Mylan Laboratories again reiterated its commitment to the estimated four (B) billion dollar acquisition of brand-name drug maker King Pharmaceuticals despite Wall Street financier Carl Icahn upping his stake in the company.
550625
Financier Carl Icahn on Friday  offered to buy the shares of generic drugmaker Mylan  Laboratories MYL.N that he does not already own for $4.9  billion, or $20 a share, according to a government filing.
402032
Mylan Laboratories Inc. (MYL.N: Quote, Profile, Research) , a maker of generic drugs, and King Pharmaceutical (KG.N: Quote, Profile, Research) on Wednesday reaffirmed their commitment
708424
Elan Corp. PLC of Ireland yesterday denied it was involved in merger talks with Biogen Idec Inc. of Cambridge, seeking to squelch rumors of a possible deal just prior to the anticipated approval of Antegren, the two firms' treatment for multiple sclerosis.
19229
Walt Disney Co. President Bob Iger said on Wednesday that a new deal with Pixar Animation Studios was unlikely and that the U.S. media conglomerate had been approached to buy UK media assets.
386076
In a letter to the board of directors at Mylan Laboratories (nyse: MYL - news - people ), financier Carl Icahn questioned their silence on the recent financial restatements by King Pharmaceuticals (nyse: KG - news - people ), calling the &quot;lack of
748008
Icahn is involved in the Mylan-King Pharmaceuticals deal for his benefit only.
695477
Generic drug maker Mylan Laboratories Inc.  said on Friday it expects to raise $993.6 million after pricing a public offering of notes and common shares, with proceeds intended for global operations and potential acquisitions.
723851
Generic drug maker Mylan Laboratories Inc.  said on Friday it expects to raise $993.6 million, following a pricing of its public offerings of notes and shares.
443606
Mylan Laboratories Inc. may have found the white knight it needs to check Carl Icahn&#39;s attempts to kill its $4 billion plan to acquire King Pharmaceuticals Inc.
84238
Mylan Laboratories Inc. MYL.N on  Friday said its board of directors remains committed to the  purchase of King Pharmaceuticals Inc. KG.N, despite news that  billionaire investor Carl Icahn won regulatory approval to buy  up to 11.9 percent of Mylan's shares.
165524
Mylan Laboratories Inc. was one of the few drug makers whose stock closed up Friday with the sector down for a second day as fresh squabbles between veteran financier Carl Icahn and the company&#39;s board erupted.
655804
-- Mylan Laboratories  Inc.MYL.N on Wednesday said it was unlikely to complete its  $3.37 billion acquisition of King Pharmaceuticals Inc.KG.N at  the current price because of King's need to restate earnings.
629609
Business & money: Sir Richard Branson's group says it cannot continue to promise there will be no cuts if it succeeds in bid
17097
The generic drug maker&#39;s deal to buy King Pharmaceuticals was supposed to mark its arrival in the brand-name drug business. Instead, it put the spotlight on a new CEO&#39;s strategy that billionaire investor Carl Icahn doesn&#39;t like.